Long-Term Type VII Collagen Restoration to Human Epidermolysis Bullosa Skin Tissue
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In spite of advances in the molecular diagnosis of recessive dystrophic epidermolysis bullosa (RDEB), an inherited blistering disease due to a deficiency of type VII collagen at the basement membrane zone (BMZ) of stratified epithelium, current therapy is limited to supportive palliation. Gene delivery has shown promise in short-term experiments; however, its long-term sustainability through multiple turnover cycles in human tissue has awaited confirmation. To characterize approaches for long-term genetic correction, retroviral vectors were constructed containing long terminal repeat-driven full-length and epitope-tagged COL7A1 cDNA and evaluated for durability of type VII collagen expression and function in RDEB skin tissue regenerated on immune-deficient mice. Type VII collagen expression was maintained for 1 year in vivo, or over 12 epidermal turnover cycles, with no abnormalities in skin morphology or self-renewal. Type VII collagen restoration led to correction of RDEB disease features, including reestablishment of anchoring fibrils at the BMZ. This approach confirms durably corrective and noninjurious gene delivery to long-lived epidermal progenitors and provides the foundation for a human clinical trial of ex vivo gene delivery in RDEB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“The insertional activation of the LMO2 proto-oncogene and subsequent induction of leukemia in patients undergoing a hematopoietic stem cell human gene therapy trial (Hacein-Bey-Abina et al. , 2003a,b) precipitated a careful investigation of the use of retroviruses in human trials.”
Cited by
Advances in skin grafting and treatment of cutaneous wounds
Sun, B. K., Siprashvili, Z., & Khavari, P. A. (2014) · Science · doi:10.1126/science.1253836 · Cited by 972
Self-citationCell-Extracellular Matrix Interactions in Normal and Diseased Skin
Watt, F. M., & Fujiwara, H. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005124 · Cited by 384
Stem Cells in Skin Regeneration, Wound Healing, and Their Clinical Applications
Ojeh, N., Pastar, I., Tomic-Canic, M., & Stojadinovic, O. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161025476 · Cited by 303
Siprashvili, Z., Nguyen, N. T., Gorell, E. S., Loutit, K., Khuu, P., Furukawa, L. K., Lorenz, H. P., Leung, T. H., Keene, D. R., Rieger, K. E., et al. (2016) · JAMA · doi:10.1001/jama.2016.15588 · Cited by 222
Self-citationUmegaki-Arao, N., Pasmooij, A. M. G., Itoh, M., Cerise, J. E., Guo, Z., Levy, B., Gostyński, A., Rothman, L. R., Jonkman, M. F., & Christiano, A. M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009342 · Cited by 123
“ScienceTr of gene therapy including transplantation of genetically modified epidermal keratinocytes using retroviral vector (8, 9) and induced pluripotent stem cell (iPSC)–based gene therapy (10) were previously reported.”
Background
Metadata
- Authors
- Siprashvili, Z., Nguyen, N. T., Bezchinsky, M. Y., Marinkovich, M. P., Lane, A. T., & Khavari, P. A.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2010-10
- Volume
- 21
- Issue
- 10
- Pages
- 1299-1310
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2065114016
- Cited by
- 93
- References
- 2
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.